De-Risking Oral Drug Formulation with Absorption-Driven Development

[Article Title]

Late-stage surprises in oral drug development can derail timelines when formulation changes impact absorption. This document shows how integrating permeability testing early helps reduce that risk and better predict in vivo performance. Using telmisartan as a model, it highlights how common excipients influence both solubility and permeability—and how early insights can guide smarter formulation decisions. It also demonstrates how tools like PAMPA and dissolution-permeation assays support more informed development. Download to see how a permeability-driven approach can improve formulation strategy, align in vitro and in vivo results, and reduce uncertainty throughout development.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.